Effect of terbutaline administered from metered dose inhaler (2 mg) and subcutaneously (0.25 mg) on tracheobronchial clearance in mild asthma. 1987

D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
Department of Thoracic Medicine, Royal Free Hospital, London.

Tracheobronchial mucus clearance was measured in nine mild asthmatics, using an objective radioaerosol technique, on 3 separate days at intervals of 1 week. Immediately after radioaerosol inhalation, drug or placebo was administered via subcutaneous injection (SC) plus metered dose inhaler (MDI)--2 puffs. Three randomized treatments were used: saline placebo SC plus 2 mg terbutaline by MDI (1 mg per puff); 0.25 mg terbutaline SC plus placebo (propellants and surfactant only) by MDI; and double placebo. Changes in lung mucociliary clearance showed an inverse relationship to baseline clearance of both proximal and distal ciliated airways following inhaled terbutaline, whereas terbutaline SC related inversely only to baseline clearance of the distal ciliated airways. This may reflect the surface concentrations of drug, established by each route.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009079 Mucociliary Clearance A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers. Mucociliary Transport,Clearance, Mucociliary,Clearances, Mucociliary,Mucociliary Clearances,Mucociliary Transports,Transport, Mucociliary,Transports, Mucociliary
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
February 1989, Annals of allergy,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
November 1985, Annals of allergy,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
May 1994, The Journal of pediatrics,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
July 1980, Thorax,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
July 1988, Arerugi = [Allergy],
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
December 1994, Thorax,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
March 1995, Archives of disease in childhood,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
January 1982, European journal of clinical pharmacology,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
December 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
D Pavia, and J E Agnew, and P P Sutton, and M T Lopez-Vidriero, and M M Clay, and M Killip, and S W Clarke
June 1994, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace,
Copied contents to your clipboard!